• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[异基因或自体骨髓移植维持急性髓系白血病缓解]

[Maintenance of remission in acute myeloid leukemia by allogeneic or autologous bone marrow transplantation].

作者信息

Beelen D W, Quabeck K, Mahmoud H K, Sayer H G, Kraft J, Graeven U, Grosse-Wilde H, Quast U, Schaefer U W

机构信息

Klinik und Poliklinik für Knochenmarktransplantation, Universitätsklinikum Essen.

出版信息

Dtsch Med Wochenschr. 1991 Mar 15;116(11):401-10. doi: 10.1055/s-2008-1063625.

DOI:10.1055/s-2008-1063625
PMID:2001649
Abstract

Over a 10-year period 120 patients (58 women, 62 men; median age 33 [14-53] years) with acute myeloid leukaemia were treated by allogenic (n = 90) or autologous bone marrow transplantation to maintain remission. After a median observation time of 41 (11-126) months 64 patients (53%) remain alive without recurrence of leukaemia. Ten years after allogenic transplantation performed during the first complete remission the probability of disease-free survival is 50 +/- 8%, as compared with 50 +/- 9% at 4.5 years after autologous transplantation. Significant factors influencing disease-free survival after allogenic transplantation during the first complete remission were the time interval up to the onset of remission and the length of the remission before transplantation. The chance of disease-free survival after allogenic transplantation in the second complete remission does not so far differ from the results achieved by transplantation in the first complete remission. The risk of recurrence after autologous transplantation in the first complete remission (47 +/- 10%) is significantly higher than that following allogenic transplantation (18 +/- 10%, P less than 0.0001). Acute graft versus host reactions occurred in 16% and chronic reactions in 36% of patients after allogenic transplantation. The mortality was 38% after allogenic transplantation and 7% after autologous transplantation.

摘要

在10年期间,120例急性髓性白血病患者(58例女性,62例男性;中位年龄33[14 - 53]岁)接受了异基因(n = 90)或自体骨髓移植以维持缓解状态。经过中位观察时间41(11 - 126)个月后,64例患者(53%)存活且白血病未复发。在首次完全缓解期进行异基因移植10年后,无病生存率为50±8%,而自体移植4.5年后为50±9%。影响首次完全缓解期异基因移植后无病生存的重要因素是至缓解开始的时间间隔以及移植前缓解的持续时间。目前,第二次完全缓解期异基因移植后的无病生存机会与首次完全缓解期移植所取得的结果并无差异。首次完全缓解期自体移植后的复发风险(47±10%)显著高于异基因移植后(18±10%,P<0.0001)。异基因移植后,16%的患者发生急性移植物抗宿主反应,36%的患者发生慢性反应。异基因移植后的死亡率为38%,自体移植后的死亡率为7%。

相似文献

1
[Maintenance of remission in acute myeloid leukemia by allogeneic or autologous bone marrow transplantation].[异基因或自体骨髓移植维持急性髓系白血病缓解]
Dtsch Med Wochenschr. 1991 Mar 15;116(11):401-10. doi: 10.1055/s-2008-1063625.
2
Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission.化疗与自体或异基因骨髓移植在初治缓解期急性髓系白血病治疗中的比较。
N Engl J Med. 1998 Dec 3;339(23):1649-56. doi: 10.1056/NEJM199812033392301.
3
Long-term results in non randomized patients with acute myelogenous leukemia: a single institution experience.急性髓性白血病非随机分组患者的长期结果:单机构经验
Ann Ital Med Int. 1998 Jul-Sep;13(3):146-51.
4
[Allogenic bone marrow transplantation versus autograft in acute lymphoblastic leukemia, in second remission in 113 children. Results of the Grupo Español de Transplante de Medula Niños (GETMON)].[113名处于第二次缓解期的儿童急性淋巴细胞白血病患者接受异基因骨髓移植与自体移植的对比研究。西班牙儿童骨髓移植协作组(GETMON)的研究结果]
Sangre (Barc). 1996 Apr;41(2):101-8.
5
Use of peripheral blood stem cells for autologous transplantation in acute myeloid leukemia patients allows faster engraftment and equivalent disease-free survival compared with bone marrow cells.与骨髓细胞相比,在急性髓系白血病患者中使用外周血干细胞进行自体移植可实现更快的植入和相当的无病生存期。
Bone Marrow Transplant. 1999 Sep;24(5):467-72. doi: 10.1038/sj.bmt.1701920.
6
High dose chemotherapy with busulfan, cyclophosphamide, and etoposide as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remission.以白消安、环磷酰胺和依托泊苷进行大剂量化疗作为首次完全缓解的急性髓系白血病患者异基因骨髓移植的预处理方案。
Clin Cancer Res. 1997 Dec;3(12 Pt 2):2671-5.
7
[Effectiveness of allogeneic bone marrow transplantation in patients with acute leukemia in complete remission and in patients with chronic myeloid leukemia during the chronic phase].
Ter Arkh. 1999;71(7):27-32.
8
Retrospective evaluation of autologous bone marrow transplantation vs allogeneic bone marrow transplantation from an HLA identical related donor in acute myelocytic leukemia. A study of the European Cooperative Group for Blood and Marrow Transplantation (EBMT).急性髓细胞白血病中自体骨髓移植与来自人类白细胞抗原(HLA)匹配的相关供体的异基因骨髓移植的回顾性评估。欧洲血液与骨髓移植协作组(EBMT)的一项研究。
Bone Marrow Transplant. 1996 Jul;18(1):111-7.
9
Second allogeneic hematopoietic stem cell transplantation as treatment for leukemia relapsing following a first transplant.第二次异基因造血干细胞移植作为首次移植后复发白血病的治疗方法。
Bone Marrow Transplant. 2000 Jan;25(1):41-5. doi: 10.1038/sj.bmt.1702101.
10
Long-term follow-up of patients undergoing allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission after cyclophosphamide-total body irradiation and cyclosporine.接受环磷酰胺-全身照射及环孢素治疗后首次完全缓解的急性髓系白血病患者接受异基因骨髓移植的长期随访
Bone Marrow Transplant. 1996 Oct;18(4):741-6.

引用本文的文献

1
Autotransplants with peripheral blood stem cells and clinical results obtained in children: a review.儿童外周血干细胞自体移植及其临床结果综述
Eur J Pediatr. 1993 Jul;152(7):546-54. doi: 10.1007/BF01954078.